Prognostic value of thymidine phosphorylase expression in breast carcinoma

✍ Scribed by Qifeng Yang; Mattia Barbareschi; Ichiro Mori; Francesco Mauri; Maurizio Muscarà; Misa Nakamura; Yasushi Nakamura; Goro Yoshimura; Takeo Sakurai; Orazio Caffo; Enzo Galligioni; Paolo Dalla Palma; Kennichi Kakudo

• Publisher: John Wiley and Sons
• Year: 2001
• Tongue: French
• Weight: 488 KB
• Volume: 97
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.1633

✦ Synopsis

Abstract

Thymidine phosphorylase (TP), also known as platelet‐derived endothelial cell growth factor (PD‐ECGF), is an enzyme that catalyzes the reversible dephosphorylation of thymidine, deoxyuridine and their analogs. TP has also angiogenic properties, although the precise mechanism by which it promotes angiogenesis is not known. We examined TP expression using immunohistochemistry (654‐1 Mab) in 182 invasive breast carcinomas (67 N0 and 115 N1/2; median follow‐up 78 months [range, 3–177]; 51 patients treated with adjuvant systemic cyclophosphamide, methotrexate and 5‐fluorouracil [CMF] chemotherapy and 82 with tamoxifen). High TP expression was found in 142 cases (78%) and correlated with lower histologic grade and low p53 expression. No correlation was found between TP expression and vascular density. TP‐positive tumors had a significant increase in both disease‐free survival (DFS; p = 0.0025) and overall survival (OS; p = 0.0070) in the total cohort of patients and in the subgroups of node‐positive patients and patients treated with CMF adjuvant therapy; no significant difference in either DFS or OS was observed in patients without CMF treatment. Our findings suggest that TP has little effect on tumor angiogenesis of breast carcinoma, whereas it could represent an interesting marker that could predict response to CMF chemotherapy. © 2001 Wiley‐Liss, Inc.